Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study

Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA
F. Hoffmann-La Roche Ltd, Basel
Department of translational and precision medicine, Sapienza University, Rome
BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC
4th Department of Internal Medicine—Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
Universitaria San Martino, Genoa
Cross Cancer Institute, University of Alberta, Edmonton, AB
Institut Català d’Oncologia, Institut d’Investigació Biomédica de Bellvitge, Universitat de Barcelona, Hospitalet de Llobregat, Barcelona
Fudan University Shanghai Cancer Center, Shanghai
Hematology-Oncology, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
Department of Patient Safety and Management, Kindai University Hospital and Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka
Genentech, Inc., South San Francisco, CA
F. Hoffmann-La Roche Ltd, Basel
F. Hoffmann-La Roche Ltd, Basel
F. Hoffmann-La Roche Ltd, Basel
F. Hoffmann-La Roche Ltd, Basel
Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin
First Department of Medicine, Charles University General Hospital, Prague, Czech Republic
Vol. 107 No. 7 (2022): July, 2022